PRESS RELEASE

GE invests in Nanosonics' novel trophon® EPR technology to help grow sales and marketing in North America

Builds on GE Healthcare's earlier commitment to help establish trophon® EPR as the accepted technology for ultrasound probe reprocessing in North America

Sydney, Australia, Wauwatosa, WI and Menlo Park, CA – August 14, 2013 – GE Healthcare and GE Ventures today announced a new sales and marketing investment to accelerate the roll-out of trophon® EPR, a unique system for ultrasound transducer disinfecting developed by Australian-based Nanosonics Limited [ASX: NAN].

This new investment includes the establishment of a dedicated GE Healthcare *trophon® EPR* sales organization to cover the North American market in collaboration with the current GE Healthcare Ultrasound sales team.

In support of the investment made in Nanosonics in June 2012, GE Ventures is making a non-dilutive investment to fund a fully integrated marketing program to accelerate the North American growth strategy.

This investment follows the adoption by a growing number of luminary customers across the US and Canada as healthcare providers become increasingly aware of the benefits of trophon® EPR.

Anders Wold, president and CEO of GE Ultrasound said, "GE Healthcare is pleased to be offering this new technology in ultrasound probe reprocessing which is effective, efficient and environmentally friendly. Through our investments in highly innovative technologies and as the exclusive distributor of trophon® EPR in North America, GE Ultrasound is further demonstrating our commitment to providing solutions to our customers in order to improve patient care and clinical workflow."

Ron Weinberger, managing director of Nanosonics said, "Hospital acquired infections (HAIs) have increased by 36% in the last 20 years and are consuming more healthcare dollars each year. Sonographers can see over ten patients a day, resulting in an increased need for an efficient and safe system to disinfect the ultrasound transducer thoroughly between patients. Nanosonics has developed trophon® EPR, an innovative ultrasound disinfecting system, that we believe will significantly help lower the risk of HAIs. This investment in sales and marketing enables us to leverage the joint expertise of Nanosonics and GE to drive the awareness and adoption of trophon® EPR as the new standard of care for ultrasound probe reprocessing in North America."

Nanosonics' trophon® EPR technology is unique in that it:

- **Helps improve turnaround time**: The system takes a total of 7 minutes to disinfect between patients. This is about half the time compared to traditional disinfection techniques, meaning more patients can get scanned in a day.
- **Helps improve patient & staff safety**: an automated system that provides disinfection of both handle and probe to reduce the chance of cross contamination and also eliminate exposure to toxic chemicals and fumes

- **Convenient**: the trophon® EPR can be placed in the same room as the ultrasound machine. Other methods require a separate disinfection room due to the powerful chemicals that are used.
- **Environmentally friendly**: The system breaks down residual disinfectants into water and oxygen which is safer for the environment, patient and sonographer.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com

About GE Ventures
GE Ventures is committed to identifying, scaling and accelerating ideas that will make the world work better. Focused on the areas of software and analytics, advanced manufacturing, energy and healthcare, GE Ventures helps entrepreneurs and start-ups succeed by providing access to GE's technical expertise, capital and opportunities for commercialization through GE's global network of business, customers and partners. GE Ventures is headquartered in Menlo Park, CA. For more information, please visit http://www.ge.com/company/ge-ventures.

About Nanosonics
Nanosonics is a leading expert in infection control technology solutions. Based in Sydney, Australia and listed on the Australian Securities Exchange, Nanosonics (ASX: NAN) has developed easy-to-use, environmentally friendly and quality assured products for the infection control market since 2009. Nanosonics is committed to preventing hospital acquired infections (HAIs) which occur during medical care and are caused by variety of common and unusual bacteria, fungi, and viruses. Nanosonics' first product, the trophon® EPR, represents the next generation in ultrasound probe disinfection as it delivers fast, safe and eco-friendly probe disinfection at the point of care. It is currently available in North America, Europe, Australia and New Zealand and selected markets in Asia. Using Nanosonics patented 'NanoNebulant' disinfection technology, the trophon® EPR uses a super fine mist to disinfect ultrasound probes to the required standard. This unique technology disinfects the entire ultrasound probe – the shaft and handle – in seven minutes. Only water and oxygen are produced as by-products. Nanosonics is looking to develop disinfection products for application across a range of industries. For more information: www.nanosonics.com.au

Caution Concerning Forward-Looking Statements*:*
This document contains "forward-looking statements" – that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: current economic and financial conditions, including volatility in interest and exchange rates, commodity and equity prices and the

value of financial assets; potential market disruptions or other impacts arising in the United States or Europe from developments in the European sovereign debt situation; the impact of conditions in the financial and credit markets on the availability and cost of General Electric Capital Corporation's (GECC) funding and on our ability to reduce GECC's asset levels as planned; the impact of conditions in the housing market and unemployment rates on the level of commercial and consumer credit defaults; changes in Japanese consumer behavior that may affect our estimates of liability for excess interest refund claims (Grey Zone); pending and threatened litigation against WMC, including increased activity by securitization trustees; our ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so; the adequacy of our cash flow and earnings and other conditions which may affect our ability to pay our quarterly dividend at the planned level; our plan to resume GECC dividends, which is subject to Federal Reserve review; the level of demand and financial performance of the major industries we serve, including, without limitation, air and rail transportation, energy generation, real estate and healthcare; the impact of regulation and regulatory, investigative and legal proceedings and legal compliance risks, including the impact of financial services regulation; strategic actions, including acquisitions, joint ventures and dispositions and our success in completing announced transactions and integrating acquired businesses; the impact of potential information technology or data security breaches; and numerous other matters of national, regional and global scale, including those of a political, economic, business and competitive nature. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.

Media Contacts

Arvind Gopalratnam
GE Healthcare Ultrasound Communications Leader
Arvind.gopalratnam@ge.com
+1-262-501-0777

Ron Weinberger, CEO or McGregor Grant, CFO, on +61 2 8063 1600
Kyahn Williamson, Media Relations, Buchan Consulting on +61 3 9866 4722